BIRAC CTN - Diabetology

Quarterly Newsletter : 11 (September 2023 - November 2023

Introduction

The Biotechnology Industry Research Assistance Council (BIRAC), established by NBM, the Department of Biotechnology (DBT), Government of India, is home to the Clinical Trial Network (CTN) for Hospital Based Trial in Diabetology. BIRAC serves as an interface agency, empowering emerging biotech companies to engage in innovative and strategic research while addressing demands for product development that are pertinent to the country.

The Multi Centric Diabetes Registry with seven hospitals across India has been operational for more than two years. As of November 30th, 2023, 24,840 people from various site within the CTN Diabetology were enrolled in this registry. Information on patients with Type 1 and Type 2 Diabetes mellitus is being gathered by this registry.

Our research teams across multiple center's delve into discovering the key trends and emerging patterns in diabetes in India through innovative approaches to identifying risk factors. We're committed in advancing diabetes knowledge collectively.

Explore the success stories of our network, where researchers and healthcare professionals from seven center's came together to tackle diabetes challenges and learn about the impact of these joint efforts on patient care of diabetes and its outcomes through the series of our newsletter.

Content

Introduction Page 1

Journey so far Page 2

Recent Events Pages 3-14


Future plans, Upcoming Events Page 15

JOURNEY SO FAR

Events held : From 1st Sept 2023 to 30th Nov 2023

Diabetes Registry


The Hospital Based Multi Centric Diabetes Registry has captured baseline data of 24,840 participants and follow up data of 884 participants as of 30th November 2023



2

Pfizer-Capability building session hosted by MS Ramaiah medical college and hospitals


First Educational Webinar: "Ethics in Clinical research: The foundation and current issues" on 20th Sept 2023



The Session offered an excellent opportunity to delve into the following key areas:

- 1. Principles of Ethics
- 2. The Roles of Stakeholders in Upholding Ethics
- 3. Patient-Centric Ethics


Second Educational Webinar: "Real World Evidence– Unravelling the Essentials" on 18th Oct 2023



An in-depth investigation of Real World Evidence (RWE) and Real World Data (RWD), with a focus on related subjects such as:

- 1. Differentiating RWE and RWD
- 2. Application of Real World Evidence
- 3. Type of Real World Evidence Studies
- 4. Real World Evidence in the Indian

Third Educational Webinar: "Systematic Review and Metanalysis" on 15th Nov 2023



The theory session on systematic review and meta-analysis typically covered

- 1. The foundational principles
- 2. Methodologies
- **3.** Applications of these research approaches.

63rd Annual Conference of National Academy of Medical Sciences- NAMSCON 2023 06th- 07th October 2023




Dr Pramila Kalra received the best oral presentation award on abstract titled "**Hospital Based Multicentric Diabetes Registry from India** "at NAMSCON 2023 conference held at M S Ramaiah Medical College, Bangalore.



CAG Audit at M S Ramaiah Medical College and Hospitals Bangalore 30th October 2023



06 th PMC Meeting 31st October 2023



Patient Awareness Program for Diabetes Patients

27th October 2023 Conduced at M S Ramaiah Medical College and Hospitals, Bangalore



World Diabetes Day Program and Patient Awareness Program for Diabetes Patients on 14th,15th November2023

Conducted at SGRDUHS, Amritsar






Patient Awareness Program for Diabetes Patients on 14th November 2023, Conducted at NEIGRIHMS, Shillong



World Diabetes Day and Patient Awareness Program for Diabetes on 14th November 2023 conducted at

SIMS Hospital, Chennai











World Diabetes Day and Patient Awareness Program for Diabetes Patients 14th November 2023 Conducted at

NIMS Hospital, Trivandrum











World Diabetes Day Program on 15th November 2023 Conducted at M S Ramaiah Medical College and Hospitals, Bangalore



Accomplishment

Ongoing Academic studies in Endocrinology Department-Network Mode

To study the effect of patient education on Knowledge Attitude and Practice (KAP) of Diabetic foot care among Type 2 Diabetic Mellitus patients.

Ongoing Clinical Trials in Endocrinology Department –Network Mode

l.	WSRIVICH, Bangalore& PGIVIER, SSRIVI HOSPITAI, KOIKATA		
SI. No	Study Title	Sponsor	
1	A Randomized, controlled, Multi-	Crinetics Pharmaceuticals	
	center study to Evaluate the study		
	and Efficacy of Paltusotine in Sub-		
	ject with Non –Pharmacologically		
	Treated Acromegaly		
2	A Phase 3, Randomized, Double –	Eli Lilly	
	Blind study to Investigate the Effica-		
	cy and safety of once Daily Oral		
	LY3502970 Compared with Placebo		
	in Adult Participant with TYPE 2 Di-		
	abetes and Inadequate Glycemic		
	Control with Diet and Exercise		
	Alone		
3	The cardiovascular safety of	Novo Nordisk	
	cargrilintide 2.4 mg s.c in combina-		
	tion with obesity and established		
	cardiovascular disease		
4	A 40– week study comparing the	Novo Nordisk	
	efficacy and safety of once Icosema		
	and daily Insulin Glargine100		

MSRMCH, Bangalore& IPGMER, SSKM Hospital, Kolkata

Accomplishment

Ongoing Clinical Trials in Endocrinology Department –Network Mode

II. BMCRI, Bangalore & IPGMER, SSKM Hospital, Kolkata

Sl. No	Study Title	Sponsor
	LY3437943 Once weekly in participant with Type 2 Dia- betes and Obesity or over- weight patient	Eli Lilly

Feasibility In Network Mode

I. SGRDUHS, Amritsar & NIMS Medicity, Trivandrum

SI. No	Study Title	Sponsor
1	A Prospective, Interventional,	Square Pharma-
	Multicenter, Post marketing Clini-	ceuticals Ltd.
	cal study of Ansulin 30/70 Injec-	
	tion 100 IU/ml {Insulin Human	
	(rDNA) 30/70 100Injection} in the	
	treatment of Diabetes MellituS	
	(DM)	

Accomplishment

Feasibility In Network Mode

II. MSRMCH, Bangalore & IPGMER, SSKM Hospital, Kolkata

SI. No	Study Title	Sponsor
1	Efficacy and safety of early ini- tiation of oral semaglutide 50 mg and 25 mg once daily dose versus empagliflozin 25 mg once daily and versus metfor- min 2g in treatment native pa- tient with newly diagnosed type 2 diabetes and over weight or obesity	Novo Nordisk
2	Fixed ratio combination of Glargine and lixisenatide in adult patient with Type 2 Dia- betes	Sanofi





• To start study on "Assessment of KAP about periodontal disease among diabetic patients: A Hospital Based Multi-Centric Study"

Upcoming events

- "Global Bio India 2023" at New Delhi from 4th to 6th December 2023.
- Education Module Cardiac Metabolic Disorder-Novonordisk will be starting from the month of December 2023
- PM Monthly meeting on 6th December 2023 at 2:30 pm via Microsoft teams